There has been a paradigm shift in the management of aspirin-exacerbated respiratory
disease (AERD). It started in 2015 when the first biologic was Food and Drug Administration …

Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitis that
affects small size vessels. Only four cases of periaortitis associated with EGPA have been …

Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of anti-
neutrophil cytoplasmic antibody (ANCA) associated vasculitis characterized by eosinophil …

Background: The purpose of this study is to clarify the changes in peripheral blood
eosinophil (PBE) counts and eosinophilic granulomatosis with polyangiitis (EGPA) onset in …

Background Temporary eosinophilia is a potential adverse reaction of monoclonal antibody
therapies in the treatment of a variety of type 2 inflammatory conditions, including asthma …

The pathogenic role of p-ANCA in eosinophilic granulomatosis with polyangiitis (EGPA) is a
long-standing matter of debate. In this work, we report our real-life experience with EGPA …

Background Dupilumab has been used with significant benefit in the treatment of asthma
and chronic rhinosinusitis with nasal polyps (CRSwNP). Phase 3 clinical trials have …

Objectives To provide long-term, real-world safety and effectiveness data for mepolizumab
treatment in eosinophilic granulomatosis with polyangiitis in Japan. Methods MARS …

DEAR EDITOR, Mepolizumab, an anti-IL-5 monoclonal antibody, is recommended as both
induction and maintenance therapy for patients with eosinophilic granulomatosis with …

Background There have been multiple reports of the anti-IL4Rα agent, dupilumab, as
associated with the onset and/or progression of cutaneous T-cell lymphoma (CTCL) …